New York, September 11, 2024 - PRISM MarketView - Terns Pharmaceuticals (Nasdaq: TERN) has announced an upsized public offering of 11.9 million shares of common stock at $10.50 per share, with expected gross proceeds of approximately $150.15 million. This announcement follows positive results from the company’s Phase 1 trial of its oral weight-loss drug, TERN-601, which demonstrated statistically significant weight loss and was well tolerated by patients.
Key Highlights:
- Upsized Offering: Terns is offering 11.9 million shares at $10.50 per share, with gross proceeds expected to be around $150 million.
- Positive Trial Results: TERN-601, an oral weight-loss drug, achieved up to 5.5% weight loss over 28 days, positioning it as a strong competitor in the weight-loss market.
- Next Steps: Terns plans to use the proceeds to advance its pipeline, including TERN-601 and TERN-701, its treatment for chronic myeloid leukemia.
- Phase 2 Trials: TERN-601 will enter Phase 2 clinical trials in 2025, with more data expected at upcoming scientific conferences.
The offering is expected to close on September 12, 2024, subject to customary conditions.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities